Glow Lifetech (GLOW) investor relations material

Executive summary

• Achieved 20% year-over-year revenue growth in Q2 2026, marking the 12th consecutive quarter of growth.

• Delivered positive operating cash flow and improved operating efficiency, with a 29% reduction in total expenses.

• Fully eliminated remaining warrant overhang, simplifying the capital structure.

• Expanded national distribution, including entry into Quebec and new product launches.

Financial highlights

• Net revenue reached $522,968, up 20% from Q2 2025.

• Gross profit increased 12% to $328,309; gross margin was 63% (down from 67% in Q2 2025).

• Total expenses decreased 29% to $481,490.

• Positive cash flow from operations of $3,852, a $35,006 improvement year-over-year.

• EBITDA loss narrowed to $89,145, a 46% improvement from Q2 2025.

• Cash balance rose 51% to $1,595,479; working capital surplus of $1,806,578.

• Current ratio improved to 2.62x from 2.24x.

Outlook and guidance

• Entering H2 2026 with a strengthened financial foundation and expanding national distribution.

• Management remains focused on disciplined execution, operational efficiency, and capital-efficient growth.

• Recent Quebec entry provides a platform for future portfolio expansion.